Fallouh Healthcare is proud to announce it has secured €900,000 in funding through the prestigious Eurostars 3 programme, part of the Eureka Network for innovation.
This major grant, awarded in partnership with the Medical University of Austria, will fund the next critical phase in the development of PerDeCT — our novel device for early, reliable detection of cardiac tamponade.
Why It Matters
PerDeCT offers a breakthrough, non-invasive solution to one of the most dangerous postoperative complications in cardiothoracic surgery. By enabling earlier diagnosis of cardiac tamponade, PerDeCT can:
- Save lives by reducing delays in critical care
- Improve post-surgical outcomes
- Lighten the burden on intensive care resources
- Help clinicians act with confidence
What the Eurostars Grant Supports
This grant propels PerDeCT into its preclinical validation phase, with four core workstreams:
- Preclinical Feasibility & Safety Testing
Rigorous laboratory studies to evaluate device performance, reliability, and biological safety under clinical conditions.
- Risk Assessment & Validation
Full hazard analysis and mitigation planning to align with international medical device standards.
- FDA Submission Preparation
Development of a regulatory data package to support an Investigational Device Exemption (IDE) application and pathway toward FDA PMA or De Novo approval.
- Clinical Pathway Planning
Collaboration with cardiac surgeons and ICU specialists to ensure seamless integration into real-world clinical workflows.
In collaboration with Prof. Bruno Podesser, Medical University of Vienna.
Global Collaboration for Global Impact
Partnering with the Medical University of Austria, one of Europe’s leading academic medical institutions, ensures the highest standards of scientific and regulatory execution — setting the stage for first-in-human trials and global clinical adoption.
A Strategic Step Forward
The Eurostars award represents more than funding — it reflects confidence in Fallouh Healthcare’s vision, clinical relevance, and ability to scale internationally.
It builds on our momentum from previous grants, including:
- £500,000 Innovate UK Biomedical Catalyst Award
- £50,000 WMHTIA Innovation Accelerator Grant
With Eurostars support, Fallouh Healthcare is now positioned to advance PerDeCT toward commercial readiness — and lead a new era of smarter, safer cardiac surgery care.
Preclinical Safety & Feasibility Testing
Comprehensive lab studies to verify performance, biocompatibility, and reliability of PerDeCT under real-world clinical demands.
- Regulatory Evidence Generation
Data development to support future FDA submission, and pathway planning toward PMA/De Novo approvals.
- Risk Management & Validation
Complete hazard analysis and mitigation planning — aligned with global medical device standards.
- Clinical Integration Planning
Conduct further usability studies for seamless integration in diverse healthcare systems
- Artificial Intelligence Capabilities
Software development enabling PerDeCT to implement cutting edge artificial intelligence capabilities